Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

Detalles Bibliográficos
Autores principales: Hulin, Cyrille, Offner, Fritz, Moreau, Philippe, Roussel, Murielle, Belhadj, Karim, Benboubker, Lotfi, Caillot, Denis, Facon, Thierry, Garderet, Laurent, Kuhnowski, Frédérique, Stoppa, Anne-Marie, Kolb, Brigitte, Tiab, Mourad, Jie, Kon-Siong, Westerman, Matthijs, Lambert, Jérôme, Pei, Lixia, Vanquickelberghe, Veronique, de Boer, Carla, Vermeulen, Jessica, Kampfenkel, Tobias, Sonneveld, Pieter, van de Donk, Niels W.C.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327738/
https://www.ncbi.nlm.nih.gov/pubmed/33657786
http://dx.doi.org/10.3324/haematol.2020.261842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327738/
https://www.ncbi.nlm.nih.gov/pubmed/33657786
http://dx.doi.org/10.3324/haematol.2020.261842

Ejemplares similares